Compare EQIX & SNY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | EQIX | SNY |
|---|---|---|
| Founded | 1998 | 1994 |
| Country | United States | France |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 103.1B | 95.7B |
| IPO Year | 2000 | 2001 |
| Metric | EQIX | SNY |
|---|---|---|
| Price | $1,023.71 | $40.15 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 34 | 10 |
| Target Price | ★ $1,234.19 | $53.61 |
| AVG Volume (30 Days) | 427.1K | ★ 2.6M |
| Earning Date | 10-28-2026 | 10-30-2026 |
| Dividend Yield | 2.04% | ★ 4.39% |
| EPS Growth | ★ 61.88 | N/A |
| EPS | ★ 9.04 | N/A |
| Revenue | ★ $5,998,545,000.00 | N/A |
| Revenue This Year | $11.09 | $2.25 |
| Revenue Next Year | $10.87 | $6.26 |
| P/E Ratio | $111.85 | ★ $6.14 |
| Revenue Growth | ★ 7.85 | N/A |
| 52 Week Low | $720.62 | $39.18 |
| 52 Week High | $1,128.68 | $52.68 |
| Indicator | EQIX | SNY |
|---|---|---|
| Relative Strength Index (RSI) | 48.22 | 34.81 |
| Support Level | $995.64 | N/A |
| Resistance Level | $1,058.34 | $45.22 |
| Average True Range (ATR) | 21.96 | 0.57 |
| MACD | 1.01 | -0.05 |
| Stochastic Oscillator | 40.80 | 27.18 |
Equinix is one of the leading providers of cloud- and carrier-neutral data centers, offering colocation and interconnection services to hyperscalers and businesses. Equinix operates 270 properties in 77 metropolitan areas across 36 countries, serving over 10,000 customers. About 70% of Equinix's revenue comes from renting physical space, which allows hyperscalers and other clients to store servers, data storage, and networking equipment. The other 30% of revenue is generated primarily through interconnection services (20%) and other managed services (10%).
Sanofi develops and markets drugs with a concentration in immunology, vaccines, and rare diseases. Although the company offers a diverse array of drugs, its highest-revenue product, Dupixent, accounts for over 30% of total sales. Profits for this immunology blockbuster drug are shared with Regeneron. About 45% of total revenue comes from the United States, 20% from Europe, and 6% from China.